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Summary
 
Mast cells are thought to contribute significantly to the pathology and mortality associated with
anaphylaxis and other allergic disorders. However, studies using genetically mast cell–deficient
WBB6F
 
1
 
-
 
Kit
 
W
 
/Kit
 
W-v
 
 and congenic wild-type (WBB6F
 
1
 
-
 
1
 
/
 
1
 
) mice indicate that mast cells
can also promote health, by participating in natural immune responses to bacterial infection.
We previously reported that repetitive administration of the c-kit ligand, stem cell factor
(SCF), can increase mast cell numbers in normal mice
 
 
 
in vivo. In vitro studies have indicated
that SCF can also modulate mast cell effector function. We now report that treatment with
SCF can significantly improve the survival of normal C57BL/6 mice in a model of acute bacte-
rial peritonitis, cecal ligation and puncture (CLP). Experiments in mast cell–reconstituted
WBB6F
 
1
 
-
 
Kit
 
W
 
/Kit
 
W-v
 
 mice indicate that this effect of SCF treatment reflects, at least in part,
the actions of SCF on mast cells. Repetitive administration of SCF also can enhance survival in
mice that genetically lack tumor necrosis factor (TNF)-
 
a
 
, demonstrating that the ability of SCF
treatment to improve survival after CLP does not solely reflect effects of SCF on mast cell–
dependent (or –independent) production of TNF-
 
a
 
. These findings identify c-kit and mast
cells as potential therapeutic targets for enhancing innate immune responses.
Key words: c-kit • innate immunity • mast cells • stem cell factor • tumor necrosis factor-
 
a
 
M
 
ast cells are thought of primarily as key effector cells
in IgE-dependent immune responses, such as those
involved in the pathogenesis of allergic disorders or in cer-
tain examples of immunity to parasites (1). However, re-
cent work has identified another facet of mast cell effector
function, the promotion of innate, or “natural”, immunity
to bacterial infection (2, 3). For example, Echtenacher et al.
(2) reported that genetically mast cell–deficient 
 
Kit
 
W
 
/Kit
 
W-v
 
mice exhibited greatly increased mortality after cecal liga-
tion and puncture (CLP)
 
1
 
 compared with wild-type mice,
and that the survival of 
 
Kit
 
W
 
/Kit
 
W-v
 
 mice in this model of
septic peritonitis was improved if the 
 
Kit
 
W
 
/Kit
 
W-v
 
 mice had
undergone adoptive repair of their peritoneal mast cell de-
ficiency before CLP. The same study also showed that the
mast cell–dependent protective response to CLP could be
greatly diminished in mice treated with antibodies to TNF-
 
a
 
(2). Prodeus et al. (4) later reported that normal levels of
mast cell activation and TNF-
 
a
 
 production in this CLP
model required an intact complement system, and that
complement C3 or C4 knockout mice had greatly increased
mortality after CLP compared with wild-type mice.
These findings indicated that a lack of mast cells, or defi-
cits in other components of innate defense mechanisms
(e.g., TNF-
 
a
 
, complement), can result in impaired natural
immunity to bacterial infection (2–5). However, these
studies did not evaluate whether, in normal animals, ma-
nipulations that can increase mast cell numbers and/or en-
hance mast cell function might improve the animals’ ability
to express innate immunity.
 
1
 
Abbreviations used in this paper:
 
 BMCMCs, mouse bone marrow-derived
cultured mast cells; CLP, cecal ligation and puncture; PMCs, peritoneal
mast cells; rrSCF, 
 
E
 
.
 
 coli
 
-derived recombinant rat stem cell factor
 
164
 
;
rrSCF-peg, polyethylene glycol-derivatized rrSCF; SCF, stem cell factor.
 
B. Echtenacher and L. Hültner contributed equally to this paper.
  
2344
 
SCF Enhances Innate Immunity
 
We therefore investigated whether repetitive administra-
tion of the c-kit ligand, stem cell factor (SCF [references 6,
7]; also known as kit ligand [reference 8], mast cell growth
factor [MGF, reference 9], or steel factor [reference 10]),
could influence the survival of mice subjected to CLP. By
acting synergistically with other growth factors, SCF can
promote the proliferation and further differentiation of he-
matopoietic progenitor cells; SCF is also critical for the
normal development of germ cells, melanocytes, and inter-
stitial cells of Cajal (6, 7). However, interactions between
SCF and c-kit are especially important in promoting mast
cell survival (11–13), proliferation (14, 15), and maturation
(14, 15), and can also enhance certain mast cell effector
functions (16–19). We previously reported that the daily
subcutaneous administration of 
 
E
 
.
 
 coli
 
–derived recombinant
rat SCF
 
164
 
 (rrSCF
 
164
 
) to normal mice or rats can increase
mast cell numbers in many anatomical sites, including the
peritoneal cavity (13, 15, 20). We now report that repeti-
tive treatment of mice with SCF can markedly improve
their survival after CLP, and that this effect of SCF treat-
ment reflects, at least in part, its actions on mast cells.
 
Materials and Methods
 
Animals.
 
C57BL/6 mice, genetically mast cell–deficient
WBB6F
 
1
 
-
 
Kit
 
W
 
/Kit
 
W-v
 
 (
 
Kit
 
W
 
/Kit
 
W-v
 
) mice, and the congenic nor-
mal WBB6F
 
1
 
-
 
1
 
/
 
1
 
 (
 
Kit
 
1
 
/
 
1
 
) mice were purchased from The
Jackson Laboratory, Bar Harbor, ME. Adult 
 
Kit
 
W
 
/
 
Kit
 
W-v
 
 mice or-
dinarily contain 
 
,
 
1.0% of the number of dermal mast cells
present in the skin of the congenic normal (
 
1
 
/
 
1
 
) mice, and have
no detectable mature mast cells in the gastrointestinal tract or
peritoneal cavity (21–23). TNF-
 
a
 
2/2
 
 mice were generated by
gene targeting, and TNF-
 
a
 
2/2
 
 and 
 
1
 
/
 
1
 
 mice were maintained on
a mixed 129/Sv 
 
3 
 
C57BL/6 genetic background (24). Mice were
kept in community cages at the Animal Care Facilities of the
Beth Israel Deaconess Medical Center or, for TNF-
 
a
 
2/2
 
 and 
 
1
 
/
 
1
 
mice, the GSF-Forschungszentrum, at light periods of 12 h and
were fed water and mouse chow ad libitum. All animal care and
experimentation was conducted in accord with current National
Institutes of Health and Beth Israel Deaconess Medical Center In-
stitutional Animal Care and Use Committee guidelines or under
official permission from the Regierung der Oberpfalz.
 
Treatment with SCF.
 
Mice received 21 daily subcutaneous in-
jections into the same area of back skin of vehicle alone (sterile
0.9% NaCl containing 0.1% BSA, fraction V, fatty acid-free [ICN
Immunobiologicals, Lisle, IL]), 
 
Escherichia coli
 
-derived recombi-
nant rat SCF
 
164
 
 (rrSCF
 
164
 
) at 50, 100, or 200 
 
m
 
g/kg per day in
150–250 
 
m
 
l of vehicle, or rrSCF
 
164
 
 that had been modified by the
covalent attachment of polyethylene glycol (rrSCF
 
164
 
-peg) to in-
crease the biological half-life of the cytokine, at 30 or 100 
 
m
 
g/kg
per day in 150–250 
 
m
 
l of vehicle (13, 15, 25). rrSCF
 
164
 
 and
rrSCF
 
164
 
-peg were from AMGEN Inc. (Thousand Oaks, CA).
 
Peritoneal Lavage.
 
Mice were killed by CO
 
2
 
 inhalation, then
the abdominal skin was washed with 70% ethanol, the peritoneum
was exposed by a 1–2-cm midline abdominal incision, and 2.0 ml
of sterile, pyrogen-free 0.9% NaCl and 8.0 ml of air were injected
into the peritoneal cavity via a 25-gauge needle. The abdomen
was massaged gently for 
 
z
 
3 min and the peritoneal fluid was re-
covered via a 22-gauge needle, stained for mast cells by Kimura
stain, and counted in a Neubauer chamber; the lavage fluid was
then cytospun and stained by May Grünwald-Giemsa stain (26).
 
Cecal Ligation and Puncture.
 
CLP was performed as previously
described (2, 27). In brief, mice were deeply anesthetized and the
cecum was exposed by a 1–2-cm midline incision on the anterior
abdomen and subjected to ligation of the distal half followed by a
single puncture with a 0.7- or 0.9-mm (for TNF-
 
a
 
2/2
 
 or 
 
1
 
/
 
1
 
mice) needle. The cecum was then replaced into the abdomen and
the wound was closed using 9-mm steel wound clips. Mice were
observed for mortality at least four times daily over a period of 14 d.
Mice that clearly were moribund were killed by CO
 
2
 
 inhalation.
Some TNF-
 
a
 
2/2
 
 and 
 
1
 
/
 
1
 
 mice were subjected to ligation of 80%
of the distal cecum followed by two punctures with a 0.9-mm
needle in order to induce a more severe bacterial peritonitis.
 
Selective Mast Cell Reconstitution of Kit
 
W
 
/Kit
 
W-v
 
 Mice. Kit
 
W
 
/Kit
 
W-v
 
mice (male, 4–6 wk old) were repaired of their mast cell defi-
ciency selectively and locally by the injection of growth factor–
dependent bone marrow–derived cultured mast cells (BMCMCs)
into the peritoneal cavity (2, 23). In brief, femoral bone marrow
cells from 
 
Kit
 
1
 
/
 
1
 
 mice were maintained in vitro for 
 
z
 
4 wk in IL-
3–containing, Con A–stimulated mouse spleen cell–conditioned
medium until mast cells represented 
 
.
 
95% of the total cells ac-
cording to staining by Giemsa (6, 16, 22). Mast cells (10
 
6
 
 in 200
 
m
 
l of Hanks’ MEM containing 0.47 g/liter Pipes instead of
NaHCo
 
3
 
 [HMEM-Pipes]) or HMEM-Pipes alone were injected
intraperitoneally and mice were used for experiments, together
with gender- and age-matched mast cell–deficient 
 
Kit
 
W
 
/Kit
 
W-v
 
and 
 
Kit
 
1
 
/
 
1
 
 mice, 4 wk after adoptive transfer of cultured mast
cells. The selectivity of the repair of the mast cell deficiency of
the 
 
Kit
 
W
 
/Kit
 
W-v
 
 mice was assessed before using the mice in exper-
iments by confirming that the adoptive transfer of BMCMCs
failed to improve the recipients’ anemia (6, 22, 23).
 
Histologic Studies.
 
After the mice had been killed, biopsy
specimens of the back skin at SCF or vehicle injection sites were
fixed in Carnoy’s fixative, processed into paraffin-embedded, Al-
cian blue–stained sections, coded so that the observer was not
aware of the identity of the individual specimens, and then exam-
ined at 400
 
3 by light microscopy to quantify mast cells per
squared millimeter of dermis (15).
Statistical Analysis. The significance of differences in the sur-
vival rates after CLP was assessed using the Mantel-Cox Logrank
test. All other data were tested for statistical significance using the
unpaired two-tailed Student’s t test. Unless otherwise specified,
all data are presented as the mean 6 SEM.
Results and Discussion
Repetitive Treatment with SCF Increases Peritoneal Mast Cell
Numbers and Enhances Survival after CLP in C57BL/6 Mice.
We first administered various doses of non–peg-derivatized
rrSCF164 (rrSCF) or peg-derivatized rrSCF164 (rrSCF-peg),
or vehicle alone subcutaneously to C57BL/6 mice daily for
21 d, then killed some of the mice for quantification of
mast cells in the peritoneal cavity and in the rrSCF or ve-
hicle cutaneous injection sites, whereas other, identically
treated, mice underwent CLP; the CLP-treated mice con-
tinued to receive daily subcutaneous injections of rrSCF,
rrSCF-peg, or vehicle for as long as they survived.
We found that rrSCF-peg was more effective than rrSCF
in increasing numbers of mast cells at the cutaneous injec-
tion sites (Fig. 1 A) or in the peritoneal cavity (Fig. 1 B).
Both rrSCF-peg and rrSCF exhibited a positive dose–
response effect on mast cell numbers at the skin injection2345 Maurer et al.
sites (Fig. 1 A), whereas rrSCF-peg gave high, but statisti-
cally indistinguishable, enhancement of numbers of perito-
neal mast cells (PMCs) at either 30 or 100 mg/kg per day
(Fig. 1 B).
Survival after CLP was significantly better in all SCF
treatment groups (compared with that in the vehicle-
treated group) except for the one that had been treated
with rrSCF at 50 mg/kg per day (Fig. 1 C). Even mice
treated with rrSCF at 100 mg/kg per day, a dose that had
little or no effect on numbers (Fig. 1 A) or percentages
(data not shown) of PMCs, exhibited z23 the survival af-
ter CLP as did vehicle-treated mice (P 5 0.01). However,
the best survival after CLP (z2.53 the level in the vehicle-
treated group, i.e., 53 vs. 15% survival at 14 d, P , 0.0001)
was observed in mice treated with rrSCF-peg at 30 mg/kg
per day (Fig. 1 C). This was also the treatment protocol
that had the greatest effect on numbers of PMCs (Fig. 1 B).
Accordingly, we used this dose of rrSCF-peg in the rest of
our studies.
Repetitive Treatment with SCF Improves Survival after CLP
in Mast Cell–reconstituted WBB6F1-KitW/KitW-v Mice, but
Not in Mast Cell–deficient KitW/KitW-v Mice. Mast cells are
distinct from virtually all other hematopoietic lineages in
that mature cells continue to express relatively high levels
of c-kit (6, 7). Moreover, at the doses tested in this report,
rrSCF has modest or no effects on numbers of circulating
leukocytes in normal mice (6). Nevertheless, it is possible
that some of the protective effects of SCF treatment in
CLP in normal mice might reflect actions of SCF on the
numbers or function of c-kit1 cell types other than mast
cells. To address this possibility, we performed two experi-
ments in which rrSCF-peg-(30 mg/kg per day) or vehicle-
treated mast cell-deficient KitW/KitW-v mice were subjected
to CLP after some of the mice had undergone adoptive
repair of their peritoneal mast cell deficiency (i.e., 1/1
BMCMC  ®  KitW/KitW-v mice) by the intraperitoneal
transfer of BMCMCs of Kit1/1 origin. The data from these
two experiments, which gave very similar results, are
pooled in Fig. 2.
SCF treatment had no significant effects on PMC num-
bers (Fig. 2 A) nor on overall or late (after day 3) survival af-
ter CLP (Fig. 2 B and Table 1) in KitW/KitW-v mice; these
mice express kit derived from the KitW-v c-kit allele, which
exhibits markedly reduced tyrosine kinase activity upon
binding of SCF (28). By contrast, both overall and late
survival were significantly better in SCF-treated 1/1
BMCMC ® KitW/KitW-v mice than in either SCF- or vehi-
cle-treated mast cell–deficient KitW/KitW-v mice (Fig. 2 B
and Table 1). Moreover, SCF treatment not only increased
PMC numbers in 1/1 BMCMC ® KitW/KitW-v mice (by
z160%, P 5 0.019; Fig. 2 A), but also increased CLP sur-
vival in these mice (from z4 to z21% at day 14, P 5
0.0811 for overall survival, P 5 0.0169 for survival after day 3,
versus the corresponding values in the vehicle-treated 1/1
BMCMC ® KitW/KitW-v mice (Fig. 2 B and Table 1).
Because the repair of the mast cell deficiency in 1/1
BMCMC ® KitW/KitW-v mice is selective (2, 22, 23), the
Figure 1. Long-term subcutaneous treatment of C57BL/6 mice (male,
6–9 wk old) with SCF results in increased numbers of dermal and perito-
neal mast cells and enhanced survival after CLP. (A and B) Some mice
were killed after the last of 21 daily subcutaneous injections with vehicle,
rrSCF (50, 100, or 200 mg/kg per day) or rrSCF-peg (30 or 100 mg/kg
per day) for assessment of (A) the numbers of mast cells/mm2 of dermis at
the site of injections and (B) the numbers of mast cells in peritoneal lavage
fluid; data in A also include values for some mice in C that died within 2 d
of CLP. Numbers of mice per group are indicated inside the bars; in A,
fold change (i.e., value for SCF-treated group/value for vehicle-treated
group) is given in parentheses. ***P , 0.005 versus values for mice treated
with vehicle alone. (C) Some mice (male, 6–9 wk old) were treated daily
for 21 d before, and for 14 d or until death after, CLP (z50% ligation,
single puncture with a 0.7-mm needle); mice received subcutaneous in-
jections of vehicle, 50, 100, or 200 mg/kg per day rrSCF, or 30 or 100
mg/kg per day rrSCF-peg (n 5 138, 18, 58, 30, 30, and 30, respectively).
Data were pooled from at least three independent experiments per treat-
ment group. PLF, peritoneal lavage fluid.
Figure 2. Long-term subcutaneous treatment with SCF increases the
numbers of mast cells in the peritoneal lavage fluid, and survival after
CLP, in wild-type Kit1/1 mice and in mast cell–reconstituted KitW/KitW-v
mice, but not in mast cell–deficient KitW/KitW-v mice. (A) Some mice
(male, 11–13 wk old at time of death or CLP) were killed after the last of
21 daily subcutaneous injections with vehicle or rrSCF-peg (30 mg/kg
per day) for assessment of the numbers of mast cells in peritoneal lavage
fluid. Numbers of mice per group are indicated inside the bars. (B) Some
mice were treated daily for 21 d before, and for 14 d or until death after,
CLP (z50% ligation, single puncture with a 0.7-mm needle). P values in
parentheses are for survival after day 3. Data were pooled from two inde-
pendent experiments per treatment group. MC, mast cell; PLF, peritoneal
lavage fluid.2346 SCF Enhances Innate Immunity
adoptively transferred mast cells are the only cellular lineage
in these mice that express the wild-type kit. Accordingly,
the ability of SCF treatment to enhance survival after CLP
in 1/1 BMCMC ® KitW/KitW-v mice must reflect actions
of SCF treatment on mast cells. Indeed, CLP survival in
SCF-treated 1/1 BMCMC ® KitW/KitW-v mice was not
significantly different (albeit somewhat lower) than that in
SCF-treated wild-type mice (Fig. 2 B and Table 1). How-
ever, compared with results in C57BL/6 mice, treatment
of Kit1/1 mice with rrSCF-peg at 30 mg/kg per day had
more modest effects on both PMC numbers (compare Fig.
2 A with Fig. 1 B) and survival after CLP (compare Fig. 2
B with Fig. 1 C), perhaps reflecting strain differences in
these responses to SCF treatment. Note also that despite
having higher numbers of PMCs (Fig. 2 A), vehicle-treated
1/1 BMCMC ®  KitW/KitW-v mice had significantly
poorer survival 14 d after CLP than did vehicle-treated
Kit1/1 mice (z4 vs. 30%, P , 0.0001 for overall survival
and P 5 0.0846 for after day 3 survival). A number of fac-
tors may have contributed to this finding, including phe-
notypic/functional differences between the endogenous
PMCs in Kit1/1 mice and the adoptively transferred, in
vitro–derived mast cells in the 1/1 BMCMC ® KitW/
KitW-v mice (15, 23).
Repetitive Treatment with SCF Improves Survival after CLP
in TNF-a2/2 Mice. Several lines of evidence indicate that
TNF-a represents one important mediator of mast cell–
dependent host resistance in CLP and other models of innate
immunity to bacteria (2–4). In support of this hypothesis,
we found that TNF-a2/2 mice exhibited significantly
impaired survival after the standard CLP procedure (50%
ligation, one needle puncture), in comparison to the cor-
responding wild-type mice (Fig. 3 A). To assess the extent
to which the effects of SCF treatment on CLP survival
might be TNF-a dependent, we performed two experi-
ments in which survival after CLP was compared in vehi-
cle- or rrSCF-peg– (30 mg/kg per day) treated TNF-a2/2
or  1/1 mice. Both experiments gave very similar results,
which are pooled in Fig. 3, B–D.
These experiments used a more severe CLP procedure
(80% ligation, two punctures with a 0.9-mm needle) in or-
der to observe better any favorable effect of SCF treatment
on survival. In these experiments, in contrast to those
shown in Fig. 3 A, vehicle-treated TNF-a1/1 mice exhib-
ited only marginally enhanced overall survival (P 5 0.0655)
compared with vehicle-treated TNF-a2/2 mice (Fig. 3 B).
However, SCF treatment resulted in improved survival after
CLP in both TNF-a2/2 mice (P , 0.0001 versus vehicle-
treated TNF-a2/2 mice) and TNF-a1/1 mice (P 5 0.0119
versus vehicle-treated TNF-a1/1 mice). Indeed, SCF treat-
ment had an even more striking effect on survival after CLP
in TNF-a2/2 mice than in the wild-type controls (Fig. 3 B).
Notably, treatment with rrSCF-peg at 30 mg/kg per day did
not significantly increase numbers of PMCs in TNF-a2/2
or  1/1 mice, possibly in part because “baseline” levels of
PMCs (e.g., in vehicle-treated mice) were already substan-
tially higher in TNF-a2/2 or 1/1 mice than in C57BL/6
mice (compare Fig. 3 C with Fig. 1 B). On the other hand,
SCF treatment did greatly increase mast cell numbers at skin
injection sites in TNF-a2/2 and 1/1 mice (Fig. 3 D).
Conclusions. In C57BL/6 mice, repetitive treatment
with SCF significantly enhanced survival after CLP roughly
in parallel with the ability of such treatment to increase
numbers of PMCs. However, improved survival after CLP
was also seen in C57BL/6 mice treated with 100 mg/kg per
day of non–peg-derivatized rrSCF, and in TNF-a2/2 or
TNF-a1/1 mice treated with 30 mg/kg per day of rrSCF-
peg, even though these SCF-treated mice did not exhibit
significantly increased numbers of PMCs. The latter find-
ings strongly suggest that actions of SCF treatment other
than simply the expansion of PMC numbers can contribute
to the ability of this agent to enhance survival in CLP.
These alternative consequences of SCF treatment in this
model of innate immunity may include effects on mast cell
Table 1. Significance (P Values, Mantel-Cox Logrank Test) of Differences in Overall or Late-phase (.3 d after CLP) Survival in the Mice 
Shown in Fig. 2 B
Overall survival
KitW/KitW-v
(vehicle)
KitW/KitW-v
(SCF)
KitW/KitW-v 1
MCs (vehicle)
KitW/KitW-v 1
MCs (SCF)
Kit 1/1
(vehicle)
Kit 1/1
(SCF)
KitW/KitW-v (vehicle) – 0.7113 0.0325 0.0015 0.0001 ,0.0001
KitW/KitW-v (SCF) 0.6104* – 0.0634 0.0076 0.0005 0.0001
KitW/KitW-v 1 MCs (vehicle) 0.5151* 0.0397* – 0.0811 0.0124 0.0029
KitW/KitW-v 1 MCs (SCF) 0.0084* 0.0018* 0.0169* – 0.4274 0.1719
Kit1/1 (vehicle) 0.0846* 0.0015* 0.0515* 0.5675* – 0.4648
Kit1/1 (SCF) 0.0019* 0.0023* 0.0023* 0.6892* 0.3158* –
MCs, mast cells.
*Late-phase survival (.3 d after CLP).2347 Maurer et al.
effector function (16–20); they also may include actions of
SCF on c-kit1 lineages other than mast cells. For example,
the CD56bright subset of human natural killer cells expresses
c-kit and can exhibit enhanced IFN-g production in re-
sponse to stimulation with SCF (29, 30); however, we have
no data that would permit us to speculate about the rele-
vance of these in vitro findings in human cells to our in
vivo study in mice.
On the other hand, the experiments with 1/1
BMCMC ® KitW/KitW-v mice indicate that at least some
of the critical effects of SCF on CLP survival can reflect
actions of SCF on mast cells. Thus, KitW/KitW-v mice ex-
hibited no protective effect of SCF treatment on survival
after CLP unless the animals had first been repaired of their
PMC deficiency; in this setting, only the adoptively trans-
ferred mast cells of wild-type origin expressed normal kit,
and therefore could have responded normally to SCF treat-
ment.
Our studies also indicate that treatment with SCF can
enhance survival after CLP even in mice that genetically
lack TNF-a, indicating that SCF treatment must be able to
augment mechanisms of host defense in innate immunity
that can be mobilized independently of TNF-a. Finally, in
confirmation of the results of our earlier experiments with
WCB6F1-1/1 mice (20), we found that mice treated with
rrSCF-peg (30 mg/kg per day for 21 d) did not appear to
be at substantially increased risk (versus vehicle-treated
mice) for death when IgE-dependent systemic anaphylaxis
was induced by intraperitoneal challenge with specific anti-
gen (our unpublished data).
These findings are the first to show that survival in a
model of innate immunity can be enhanced by treatment
with SCF, a cytokine with diverse effects on mast cells, as
well as many other cell types. These data are also the first to
show that normal animals that have been treated to develop
higher than baseline levels of mast cells can exhibit en-
hanced resistance to bacterial infection. Although great
caution must be exercised when extrapolating from mouse
studies to human medicine, our findings suggest a new ap-
proach for attempting to manage patients at risk for bacte-
rial infection. It may be of particular interest to evaluate
SCF treatment in patients with congenital or acquired im-
munodeficiency disorders, since such individuals have been
reported to have greatly decreased numbers of mast cells in
the gastrointestinal mucosa (31).
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Figure 3. (A) Survival after CLP (z50% ligation, single puncture with
a 0.9-mm needle) in TNF-a2/2 and TNF-a1/1 mice. The data were
pooled from two independent experiments with male and female (1:1)
mice that gave similar results, one with 9–10-wk-old mice and the other
with 17–18-wk-old mice. (B) Survival after CLP (80% ligation, two
punctures with a 0.9-mm needle) in TNF-a2/2 and TNF-a1/1 mice that
received daily subcutaneous treatment (for 21 d before CLP and then
daily after CLP) with rrSCF-peg 30 mg/kg per day or vehicle. The data
were pooled from two independent experiments with male and female (1:1)
mice that gave similar results, one with 26–27-wk-old mice and the other
with 17–18-wk-old mice. (C and D) Some TNF-a2/2 and TNF-a1/1
mice were killed after the last of 21 daily injections with vehicle or
rrSCF-peg (30 mg/kg per day) for assessment of (C) the numbers of mast
cells in peritoneal lavage fluid or (D) the numbers of mast cells/mm2 of
dermis at the site of subcutaneous injections; data in D also include values
for some mice in B that died within 2 d of CLP. Numbers of mice per
group (in C and D) are indicated inside the bars and, in D, the fold
change versus values for the vehicle-treated group of the same genotype is
given in parentheses. ***P , 0.0001 versus values for mice of the same
genotype treated with vehicle alone. PLF, peritoneal lavage fluid.2348 SCF Enhances Innate Immunity
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